



Regulatory Sciences as applicable to Cannabis for Medicinal and Research Purposes

29-30 May, Malta Life Sciences Park, San Gwann, MALTA

Addressed by:

Hon Dr Deo Debattista

Parliamentary Secretary for Consumer Rights, Public Cleansing & Support for the Capital City

Professor Anthony Serracino Inglott

Chairperson, Malta Medicines Authority

Speakers and contributors:

Dr Burt Kroes, Lucinda Wells, Andrew Thornley, TOPRA

Luana Mifsud Buhagiar, Director for Advanced Scientific Initiatives, Malta Medicines Authority

Dr Mark Cilia, Director for Inspectorate and Enforcement, Malta Medicines Authority

Professor Everaldo Attard, Herbal expert, Malta Medicines Authority

Training outline

Practical overview on EU regulation of medicines and herbals, good practices, quality standards and guidance documents.

Target audience

Professionals with a patient-centered interest in cannabis for medicinal and research purposes, including representatives from industry, legal, recruitment and consultancy firms, project management, clinical and regulatory operations.

Provisional Programme 2		
09:30	Introduction and welcome	
10:00	Scope and objectives	
10:15	The regulatory framework for medicines in the EU, including distinction between authorised medicinal products and other cannabis-based products	
10:45	Medicinal product development process	
11:30	Non-clinical development	
12:15	The European clinical trials process	
13:00	Lunch	
14:00	EU Marketing Authorisation Application dossiers, including well-established use	
14:45	How medicinal products are registered and approval maintained – EU marketing application procedures (national, DCP, MRP, CP)	1
15:30	Safety surveillance	
16:00	Coffee Break	
16:15	Lifecycle management – variations, extensions	
16:45	Regulatory strategy – generics, information protection, early access, trade name scientific advice	es,
17:30	Overview and interactive quiz	
18:30	Transport from MLSP to social event	
19:30	Networking refreshments at The Sheer Bastion, Senglea	
22:30	Transport from social event to MLSP	

		30 May
09:30	Cannabis for medicinal use – the local scenario	
10:00	The scenario in the Netherlands	
10:30	Quality, Pharmacopoeial standards and EMA guidance	
11:00	CTD dossier for herbals	
11:30	GACP	
12:00	GMP with focus on cannabis dosage forms such as dried flowers and oils	
12:30	Panel discussion and Q&A	
13:00	Lunch	
14:00	Duties and responsibilities in manufacturing – QP, QA, QC	
14:30	Workshops	
16:00	Coffee Break	
16:15	Consolidation, including common pit-falls in the field	
17:00	Feedback and evaluation	
17:30	Close	